A US-based study to evaluate the risk of myelodysplastic syndrome (MDS) in patients treated with bendamustine for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Flatiron Health database

Trial Profile

A US-based study to evaluate the risk of myelodysplastic syndrome (MDS) in patients treated with bendamustine for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Flatiron Health database

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jun 2017 New trial record
    • 06 Jun 2017 Results characterizing CLL patients receiving first-line bendamustine plus rituximab therapy (n=738), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top